Anxiety & Depression Association of America

Open Label Optimization Study

Purpose

The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®

Condition

Major Depressive Disorder

Eligibility

Eligible Ages: Over 18 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Adult males or females, 18 and older, who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. 2. Confirmed primary clinical diagnosis of major depressive disorder (MDD) without psychotic features consistent with DSM-V criteria. 3. No medical conditions that would preclude the safe use of TMS. 4. Primary psychiatrist has determined TMS to be an appropriate clinical option. 5. Able to provide consent and comply with all study requirements. 6. Negative pregnancy test at the intended time of SAINT™ 5-day acute course treatment and agreement to use effective birth control during SAINT® acute therapy.

Exclusion Criteria

Have any contraindication to TMS (section 2 User Manual). 2. Have any contraindication to receiving an MRI 3. Participants with an abnormal brain MRI as determined by PI, study physician or designee. 4. Deemed by the PI, study physician or designee to be a high risk of suicide or has made a suicide attempt within the last 6 months. 5. Treatment dose with cortical depth adjustment is greater than 120% motor threshold and cannot be completed.

Study Design

Phase
Study Type: Observational
Observational Model: Other
Time Perspective: Prospective

Arm Groups

Arm	Description	Assigned Intervention
SAINT® Stimulation	All participants will receive 10 treatments per day for 5 days (M-F) of SAINT® stimulation therapy.	Device: SAINT® Neuromodulation System (NMS) The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern. Other names: TMS

Recruiting Locations

More Details

Status: Recruiting
Sponsor: Magnus Medical

Study Contact

Jessica Hawkins
650-525-4485
jessica@magnusmed.com/https://www.magnusmed.com/clinical-trials/

Detailed Description

This is a prospective, multi-center, open-label study. Up to 1000 adult subjects, in a major depressive episode, who have failed to receive satisfactory improvement from a prior antidepressant medication in the current episode, are eligible to participate in this study if they are deemed to be appropriate candidates for TMS. Overall study duration is expected to be approximately 4 years. The study duration per subject is anticipated to be approximately 1 year. Hypothesis: The SAINT® Neuromodulation System will demonstrate effectiveness in the treatment of MDD as measured by CGI-I at the end of the treatment (cessation of stimulation).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.